HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Real-World data to reveal Takhzyro's impact on rare swelling disorder
Disease control Recruiting nowThis study looks back at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who have been taking Takhzyro (lanadelumab) for at least 6 months to prevent sudden swelling attacks. Researchers want to see if the drug reduces disease activity and improves q…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 08:41 UTC
-
New hope for HAE patients: extension study tests long-term attack prevention
Disease control Recruiting nowThis study is for people with hereditary angioedema (HAE) who have already completed a prior phase 3 trial of ADX-324. It aims to see how safe and effective the drug is over a longer period, and whether it can reduce the number of swelling attacks. About 90 adults will receive ad…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
Kids with rare swelling disorder get continued access to promising preventive drug
Disease control AVAILABLEThis program allows children aged 2 to 11 with hereditary angioedema (HAE) who completed a previous study to keep receiving garadacimab to prevent sudden, painful swelling attacks. Only children who responded well and had no serious side effects are eligible. The goal is to provi…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: CSL Behring • Aim: Disease control
Last updated May 26, 2026 08:29 UTC
-
New daily pill could stop HAE attacks in their tracks
Disease control Recruiting nowThis study tests a once-daily pill called deucrictibant to prevent sudden swelling attacks in people aged 12 and older with hereditary angioedema (HAE). The goal is to see if the drug is safe and effective over the long term. About 170 participants will take the pill and be monit…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for kids with rare swelling disorder: drug trial targets attacks
Disease control Recruiting nowThis study tests a medicine called donidalorsen in 20 children aged 2 to 12 with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and helps reduce the number of swelling attacks. Participants receive the drug an…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New shot could stop HAE attacks in their tracks
Disease control Recruiting nowThis study tests a new medicine called navenibart to see if it can prevent the sudden, painful swelling attacks that people with hereditary angioedema (HAE) experience. About 145 adults and teenagers with HAE type 1 or 2 will receive either navenibart or a placebo injection for 6…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Could a single blood test speed up HAE diagnosis?
Diagnosis Recruiting nowThis study aims to see if measuring just one protein function (C1-inhibitor) can accurately diagnose hereditary angioedema (HAE), a rare condition causing sudden swelling. About 514 people in Algeria who are suspected of having HAE or have family members with it will take part. R…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: NA • Sponsor: Takeda • Aim: Diagnosis
Last updated May 22, 2026 13:55 UTC
-
Real-World study tracks lanadelumab in kids with rare swelling disorder
Knowledge-focused Recruiting nowThis study observes children aged 2 to 12 with hereditary angioedema (HAE) who are already taking the medication lanadelumab to prevent swelling attacks. Researchers will review medical records to see how long children stay attack-free and how the treatment works in everyday life…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Knowledge-focused
Last updated May 26, 2026 08:30 UTC